ZA200401550B - A combination of quetiapine and zolmitriptan. - Google Patents
A combination of quetiapine and zolmitriptan. Download PDFInfo
- Publication number
- ZA200401550B ZA200401550B ZA200401550A ZA200401550A ZA200401550B ZA 200401550 B ZA200401550 B ZA 200401550B ZA 200401550 A ZA200401550 A ZA 200401550A ZA 200401550 A ZA200401550 A ZA 200401550A ZA 200401550 B ZA200401550 B ZA 200401550B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- quetiapine
- zolmitriptan
- composition
- Prior art date
Links
- 229960001360 zolmitriptan Drugs 0.000 title claims abstract description 85
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 229960004431 quetiapine Drugs 0.000 title claims abstract description 80
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title claims abstract 54
- 150000003839 salts Chemical class 0.000 claims abstract description 118
- 238000000034 method Methods 0.000 claims abstract description 53
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 46
- 206010027599 migraine Diseases 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 58
- 239000000126 substance Substances 0.000 claims description 43
- 238000009472 formulation Methods 0.000 claims description 14
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical group [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims description 11
- 229960005197 quetiapine fumarate Drugs 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000008024 pharmaceutical diluent Substances 0.000 claims 3
- 238000002372 labelling Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract description 2
- 229940127236 atypical antipsychotics Drugs 0.000 abstract description 2
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 32
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010054956 Phonophobia Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940003675 zomig Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102855A SE0102855D0 (sv) | 2001-08-27 | 2001-08-27 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401550B true ZA200401550B (en) | 2004-11-17 |
Family
ID=20285147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401550A ZA200401550B (en) | 2001-08-27 | 2004-02-25 | A combination of quetiapine and zolmitriptan. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050020571A1 (fr) |
| EP (1) | EP1423112B1 (fr) |
| JP (1) | JP2005503391A (fr) |
| AT (1) | ATE342720T1 (fr) |
| AU (1) | AU2002326271B2 (fr) |
| CA (1) | CA2456480A1 (fr) |
| DE (1) | DE60215525T2 (fr) |
| ES (1) | ES2274081T3 (fr) |
| NZ (1) | NZ530930A (fr) |
| SE (1) | SE0102855D0 (fr) |
| WO (1) | WO2003018009A1 (fr) |
| ZA (1) | ZA200401550B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5823093B2 (ja) | 2006-03-28 | 2015-11-25 | ジャヴェリン ファーマシューティカルズ インコーポレイテッド | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
| US7495024B2 (en) | 2006-08-07 | 2009-02-24 | Via Pharmaceuticals, Inc. | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque |
| JP2012506404A (ja) * | 2008-10-22 | 2012-03-15 | ノバルティス アーゲー | 片頭痛処置用組み合わせ剤 |
| US20110091435A1 (en) * | 2008-10-24 | 2011-04-21 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of hair loss |
| US10457299B2 (en) * | 2017-02-22 | 2019-10-29 | Westinghouse Air Brake Technologies Corporation | Train stop timer |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| CA2250042A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Traitement de la douleur par l'utilisation d'une combinaison synergique d'un antipsychotique atypique et un medicament utilise dans le traitement de la douleur |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| GB9709815D0 (en) * | 1997-05-14 | 1997-07-09 | Merck Sharp & Dohme | Therapeutic method |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
-
2001
- 2001-08-27 SE SE0102855A patent/SE0102855D0/xx unknown
-
2002
- 2002-08-23 US US10/487,701 patent/US20050020571A1/en not_active Abandoned
- 2002-08-23 AT AT02760969T patent/ATE342720T1/de not_active IP Right Cessation
- 2002-08-23 DE DE60215525T patent/DE60215525T2/de not_active Expired - Lifetime
- 2002-08-23 WO PCT/SE2002/001507 patent/WO2003018009A1/fr active IP Right Grant
- 2002-08-23 ES ES02760969T patent/ES2274081T3/es not_active Expired - Lifetime
- 2002-08-23 AU AU2002326271A patent/AU2002326271B2/en not_active Ceased
- 2002-08-23 EP EP02760969A patent/EP1423112B1/fr not_active Expired - Lifetime
- 2002-08-23 NZ NZ530930A patent/NZ530930A/en not_active IP Right Cessation
- 2002-08-23 CA CA002456480A patent/CA2456480A1/fr not_active Abandoned
- 2002-08-23 JP JP2003522527A patent/JP2005503391A/ja active Pending
-
2004
- 2004-02-25 ZA ZA200401550A patent/ZA200401550B/en unknown
-
2007
- 2007-11-07 US US11/936,244 patent/US20080108596A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ530930A (en) | 2006-01-27 |
| EP1423112B1 (fr) | 2006-10-18 |
| EP1423112A1 (fr) | 2004-06-02 |
| US20080108596A1 (en) | 2008-05-08 |
| ES2274081T3 (es) | 2007-05-16 |
| US20050020571A1 (en) | 2005-01-27 |
| ATE342720T1 (de) | 2006-11-15 |
| JP2005503391A (ja) | 2005-02-03 |
| SE0102855D0 (sv) | 2001-08-27 |
| WO2003018009A1 (fr) | 2003-03-06 |
| AU2002326271B2 (en) | 2007-10-11 |
| CA2456480A1 (fr) | 2003-03-06 |
| DE60215525D1 (de) | 2006-11-30 |
| DE60215525T2 (de) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6444665B1 (en) | Method for treating pain | |
| JP5173190B2 (ja) | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 | |
| US20080108596A1 (en) | Combination of Quetiapine and Zolmitriptan | |
| BRPI0618239A2 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico | |
| JP2006515628A (ja) | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 | |
| US5990159A (en) | Use of 5HT4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
| MXPA02001649A (es) | Uso de inhibidores de monoamina oxidasa para la elaboracion de farmacos destinados al tratamiento de la obesidad. | |
| JP2002308801A (ja) | うつ病、強迫疾患および精神病の組み合わせ治療 | |
| EA003142B1 (ru) | Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения | |
| JP4048024B2 (ja) | 新規経口製剤 | |
| HU229150B1 (hu) | Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére | |
| US6054455A (en) | Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia | |
| CN1252722A (zh) | 脱羰乙氧氯雷他定在治疗尿失禁、晕动病和眩晕药剂的制备中的应用 | |
| JP2002275097A (ja) | うつ病のための多剤併用治療 | |
| RU2423146C2 (ru) | Лекарственное средство для лечения эндометриоза | |
| AU2002326271A1 (en) | A combination of quetiapine and zolmitriptan | |
| MXPA05001705A (es) | Uso de reboxetina para el tratamiento de sofocos. | |
| JP2003026602A (ja) | 睡眠時無呼吸を含む睡眠障害のための多剤併用治療 | |
| JP2011517678A (ja) | 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用 | |
| CN1216598C (zh) | 药物用途 | |
| WO1998024411A2 (fr) | Procede d'administration par voie orale de buspirone | |
| JPH04247036A (ja) | 縮瞳をおこすことなく眼圧を下げる治療方法 | |
| PT1458376E (pt) | Darifenacina para utilização no tratamento da urgência urinária induzida por bexiga hiperactiva | |
| MXPA02009811A (es) | Combinacion de farmaco para el tratamiento de dolor de cabeza que comprende un farmaco no esteroidal anti-inflamatorio. | |
| CN1418099A (zh) | 用于治疗肌纤维疼痛和慢性疲劳综合征的精选化合物 |